GUBRA.CO
Gubra A/S
1W: -6.3%
1M: +8.6%
3M: -17.4%
YTD: -12.2%
1Y: -36.7%
kr 364.80 ($56.29)
+4.60 (+1.28%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Capkr 5.9B ($907.8M)
52W Range293-571
Volume18,190
Avg Volume35,205
Beta0.16
Dividendkr 61.20
Analyst Ratings
No analyst coverage
Company Info
CEOMarkus Rohrwild
Employees260
SectorHealthcare
IndustryBiotechnology
IPO Date2023-04-04
Websitegubra.dk
Hørsholm Kongevej 11B
Horsholm 2970
DK
Horsholm 2970
DK
45 31 52 26 50
About Gubra A/S
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company was incorporated in 2008 and is based in Horsholm, Denmark.
Latest News
No recent news
Recent Insider Trades
No insider trades found